Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 9.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,126 shares of the company’s stock after acquiring an additional 1,162 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Syndax Pharmaceuticals were worth $305,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Syndax Pharmaceuticals by 2.7% during the third quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company’s stock valued at $110,968,000 after purchasing an additional 198,262 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Syndax Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,617,302 shares of the company’s stock valued at $52,523,000 after acquiring an additional 34,632 shares during the last quarter. Hudson Bay Capital Management LP boosted its stake in shares of Syndax Pharmaceuticals by 160.2% during the 3rd quarter. Hudson Bay Capital Management LP now owns 1,236,186 shares of the company’s stock worth $17,949,000 after acquiring an additional 761,186 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Syndax Pharmaceuticals by 8.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,000,000 shares of the company’s stock worth $14,520,000 after acquiring an additional 75,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Syndax Pharmaceuticals by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 506,467 shares of the company’s stock worth $7,354,000 after purchasing an additional 15,156 shares during the period.

Syndax Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:SNDX opened at $22.05 on Monday. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -7.45 and a beta of 1.01. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34. The business has a fifty day simple moving average of $22.56 and a 200 day simple moving average of $19.99.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same period in the prior year, the firm earned ($0.62) earnings per share. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SNDX shares. StockNews.com raised Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. HC Wainwright restated a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a report on Friday, April 26th. Scotiabank lowered shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $36.00 to $23.00 in a research note on Wednesday, January 31st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $34.42.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).